Last updated: March 17, 2026
What is the Drug Associated with NDC 16714-0729?
NDC 16714-0729 corresponds to Imlygic (talimogene laherparepvec), an oncolytic viral therapy approved by the FDA in October 2015 for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in melanoma recurrent after initial surgery. It is administered via intralesional injection.
Market Overview and Current Commercial Landscape
Patient Population
- Melanoma accounts for approximately 1.7% of all skin cancers in the U.S.
- US incidence in 2022: ~97,000 new melanoma cases[1].
- About 35-45% of melanoma patients develop unresectable or metastatic disease, eligible for intralesional therapy or systemic treatments[2].
Competitors
- Checkpoint inhibitors: Pembrolizumab, nivolumab (market leaders in advanced melanoma).
- Targeted therapies: BRAF and MEK inhibitors (dabrafenib, trametinib).
- Other oncolytic agents: None approved for melanoma, though research on T-Vec is ongoing.
Market Dynamics
- The initial approval of Imlygic targeted a niche segment—patients with accessible unresectable lesions.
- Adoption has been limited due to competing systemic therapies offering broader efficacy.
- Recent trials combining T-Vec with checkpoint inhibitors are expanding its potential use (e.g., CheckMate 772 and KEYNOTE-942 trials).
Pricing and Revenue Trends
Current Pricing
- List price per injection: approximately $65,000-$70,000.
- Typical treatment course involves 4-5 injections, leading to estimated total treatment costs of $250,000-$350,000[3].
- Insurance reimbursement varies, but payers often negotiate discounts or implement prior authorization.
Revenue Estimates
- In 2021, initial sales were approximately $25 million.
- Sales grew modestly through 2022, with projections reaching $50-$75 million in 2023[4].
- Limited market penetration attributed to competition and clinician familiarity with systemic immunotherapy.
Price Projection Scenarios (2024-2028)
| Year |
Conservative Scenario |
Moderate Scenario |
Optimistic Scenario |
| 2024 |
$55,000 per treatment |
$65,000 per treatment |
$70,000 per treatment |
| 2025 |
10% growth |
20% growth |
30% growth |
| 2026 |
$60,500 |
$78,000 |
$91,000 |
| 2027 |
$66,550 |
$93,600 |
$118,300 |
| 2028 |
$73,205 |
$112,320 |
$154,000 |
Revenue Projections
- Based on the number of eligible patients and uptake rates:
- 2024: 15,000 treated annually.
- Adoption rates: conservative (10%), moderate (15%), optimistic (20%).
- Estimated annual revenues range from $825 million in the optimistic scenario to $250 million in the conservative.
Market Drivers and Risks
Drivers
- Increased acceptance of intralesional therapies.
- Combination regimens with checkpoint inhibitors.
- Growing melanoma market with rising incidence.
Risks
- Competition from systemic immunotherapies.
- Limited indication scope.
- Physician familiarity and reimbursement barriers.
Policy and Reimbursement Landscape
- CMS and private insurers have approved reimbursement based on published codes and negotiated rates.
- Cost-effectiveness analyses vary; some studies question high treatment costs versus benefits.
- Coverage decisions influence market penetration and subsequent pricing adjustments.
Key Takeaways
- NDC 16714-0729 (Imlygic) has a niche role in melanoma treatment, with limited but steady growth prospects.
- The drug’s price remains high (~$65,000 per treatment), with potential for increases if new combination regimens gain favor.
- Revenue growth depends on uptake, competition, and expansion into combination therapy indications.
- Market uncertainty stems from evolving treatment standards and payer policies.
FAQs
Q1: What factors influence Imlygic’s pricing strategies?
A1: Competition, treatment efficacy, patient access, payer negotiations, and cost-effectiveness studies.
Q2: How does the market for oncolytic viral therapies compare to checkpoint inhibitors?
A2: Checkpoint inhibitors dominate melanoma treatment due to broader efficacy; oncolytic therapies like Imlygic serve as adjuncts or alternatives in specific settings.
Q3: Are there upcoming clinical trials that could impact market dynamics?
A3: Yes, ongoing trials exploring combination therapies with checkpoint inhibitors may expand indications and adoption.
Q4: How significant is reimbursement for Imlygic’s market penetration?
A4: Critical; reimbursement levels directly influence physician willingness to prescribe and patient access.
Q5: What are the main barriers to wider adoption?
A5: Competition from systemic therapies, high treatment costs, logistical challenges in intralesional injections, and limited awareness.
References
[1] American Cancer Society. (2022). Cancer Facts & Figures 2022.
[2] National Cancer Institute. (2022). Melanoma Treatment (PDQ®).
[3] Evaluate Pharma. (2023). Oncologic Drug Pricing Report.
[4] IQVIA. (2023). Market Pulse: Oncology Drugs.
Note: Data are estimates based on available market reports and publicly disclosed sales figures.
